open access

Vol 24, No 1 (2017)
Original articles — Basic science and experimental cardiology
Published online: 2016-10-17
Get Citation

Circulating microRNAs as novel biomarkers for dilated cardiomyopathy

Hua Wang, Feng Chen, Jiabin Tong, Yingying Li, Jianping Cai, Yan Wang, Peng Li, Yichun Hao, Weimeng Tian, You Lv, Jia Chong, Jiefu Yang
DOI: 10.5603/CJ.a2016.0097
·
Pubmed: 27748501
·
Cardiol J 2017;24(1):65-73.

open access

Vol 24, No 1 (2017)
Original articles — Basic science and experimental cardiology
Published online: 2016-10-17

Abstract

Background: Circulating microRNAs (miRNAs) potentially carry disease-specific information. In the current study, we aim to characterize the miRNA signature in plasma from dilated cardiomyopathy (DCM) patients and assess the possible correlation between expression levels of circulating miRNAs and symptom severity in DCM patients.

Methods: Using microarray-based miRNA expression profiling, we compared the miRNA expression levels in plasma samples from 4 DCM patients and 3 healthy controls. The expression levels of selected differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were validated independently in plasma samples from 19 DCM patients and 20 controls.

Results: We observed that plasma miR-3135b (p < 0.001), miR-3908 (p < 0.001) and miR-5571-5p (p < 0.001) were significantly upregulated in DCM patients. The area under receiver operating characteristic (ROC) curves for the 3 miRNAs ranged from 0.83 to 1.00. Moreover, miR-5571-5p levels in plasma were significantly upregulated with severe New York Heart Association (NYHA) classification (p < 0.05).

Conclusions: The circulating miRNAs (miR-3135b, miR-3908 and miR-5571-5p) have potential as diagnostic biomarkers for DCM. Additionally, miR-5571-5p correlated with NYHA classification.  

Abstract

Background: Circulating microRNAs (miRNAs) potentially carry disease-specific information. In the current study, we aim to characterize the miRNA signature in plasma from dilated cardiomyopathy (DCM) patients and assess the possible correlation between expression levels of circulating miRNAs and symptom severity in DCM patients.

Methods: Using microarray-based miRNA expression profiling, we compared the miRNA expression levels in plasma samples from 4 DCM patients and 3 healthy controls. The expression levels of selected differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were validated independently in plasma samples from 19 DCM patients and 20 controls.

Results: We observed that plasma miR-3135b (p < 0.001), miR-3908 (p < 0.001) and miR-5571-5p (p < 0.001) were significantly upregulated in DCM patients. The area under receiver operating characteristic (ROC) curves for the 3 miRNAs ranged from 0.83 to 1.00. Moreover, miR-5571-5p levels in plasma were significantly upregulated with severe New York Heart Association (NYHA) classification (p < 0.05).

Conclusions: The circulating miRNAs (miR-3135b, miR-3908 and miR-5571-5p) have potential as diagnostic biomarkers for DCM. Additionally, miR-5571-5p correlated with NYHA classification.  

Get Citation

Keywords

microRNAs, dilated cardiomyopathy, biomarkers, diagnosis

About this article
Title

Circulating microRNAs as novel biomarkers for dilated cardiomyopathy

Journal

Cardiology Journal

Issue

Vol 24, No 1 (2017)

Pages

65-73

Published online

2016-10-17

DOI

10.5603/CJ.a2016.0097

Pubmed

27748501

Bibliographic record

Cardiol J 2017;24(1):65-73.

Keywords

microRNAs
dilated cardiomyopathy
biomarkers
diagnosis

Authors

Hua Wang
Feng Chen
Jiabin Tong
Yingying Li
Jianping Cai
Yan Wang
Peng Li
Yichun Hao
Weimeng Tian
You Lv
Jia Chong
Jiefu Yang

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl